Indeed, treatment with ralimetinib or p38α genetic ablation decreases the amount of TCF7 and LEF1 available in CRC cells and thus reduces the capacity of these cells to express Wnt/β-catenin target genes, including TCF7 and LEF1 themselves (Fig. 5B). Here, LEF1 is linked to colorectal carcinoma.